CKD Bio Corp. Logo

CKD Bio Corp.

Develops APIs, intermediates, and probiotics using fermentation and synthesis.

063160 | KO

Overview

Corporate Details

ISIN(s):
KR7063160006
LEI:
Country:
South Korea
Address:
서울특별시 서대문구 충정로 8, 서울특별시

Description

CKD Bio Corp. is a pharmaceutical company specializing in fermentation and chemical synthesis technologies. The company develops and manufactures a range of products, including Active Pharmaceutical Ingredients (APIs), intermediates, and probiotics. Its API portfolio features fermentation-based products such as antibiotics, ß-lactamase inhibitors, and immunosuppressants. Leveraging extensive experience in fermentation, CKD Bio also produces next-generation probiotics using patented technology. Additionally, the company provides Contract Manufacturing (CMO) and Contract Research (CRO) services for APIs and intermediates, utilizing its cGMP-certified production facilities.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2025-09-17 00:00
투자판단관련주요경영사항
Korean HTML 7.4 KB
2025-08-14 00:00
반기보고서 (2025.06)
Korean HTML 912.4 KB
2025-07-25 00:00
영업(잠정)실적(공정공시)
Korean HTML 13.2 KB
2025-05-15 00:00
분기보고서 (2025.03)
Korean HTML 968.8 KB
2025-04-25 00:00
영업(잠정)실적(공정공시)
Korean HTML 13.2 KB
2025-04-09 00:00
투자판단관련주요경영사항 (티엠버스주200단위(클로스트리디움보툴리눔독소A형)제조판매 품목허가 신청)
Korean HTML 14.0 KB
2025-04-01 00:00
투자판단관련주요경영사항 (티엠버스주100단위(클로스트리디움보툴리눔독소A형) 제조판매 품목허가 승인)
Korean HTML 7.5 KB
2025-03-26 00:00
정기주주총회결과
Korean HTML 18.6 KB
2025-03-18 00:00
감사보고서제출
Korean HTML 11.3 KB
2025-03-18 00:00
사업보고서 (2024.12)
Korean HTML 1.3 MB
2025-02-25 00:00
주주총회소집결의
Korean HTML 7.1 KB
2025-02-25 00:00
현금ㆍ현물배당결정
Korean HTML 8.8 KB
2025-02-25 00:00
주주총회소집공고
Korean HTML 111.3 KB
2025-02-25 00:00
의결권대리행사권유참고서류
Korean HTML 89.4 KB
2025-01-24 00:00
매출액또는손익구조30%(대규모법인은15%)이상변경
Korean HTML 11.8 KB

Automate Your Workflow. Get a real-time feed of all CKD Bio Corp. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CKD Bio Corp.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CKD Bio Corp. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

BELITE BIO, INC Logo
Clinical-stage biopharma developing therapies for retinal and metabolic diseases.
United States of America
BLTE
Benitec Biopharma Inc. Logo
A clinical-stage biotech developing genetic medicines to silence disease-causing genes.
United States of America
BNTC
BeOne Medicines Ltd. Logo
Global oncology company that discovers, develops, and delivers cancer treatments.
United States of America
ONC
BerGenBio Logo
Clinical-stage biopharma that developed selective AXL kinase inhibitors for cancer.
Norway
BGBIO
Beximco Pharmaceuticals Ltd. Logo
Manufacturer of generic drugs, APIs, and specialized products for global markets.
Bangladesh
BXP
BeyondSpring Inc. Logo
Clinical-stage biopharma company developing immuno-oncology cancer therapies.
United States of America
BYSI
BGM Group Ltd. Logo
A holding company focused on technology and biopharmaceutical manufacturing.
United States of America
BGM
Bicara Therapeutics Inc. Logo
Clinical-stage biopharma developing dual-action biologics for solid tumors.
United States of America
BCAX
BICYCLE THERAPEUTICS PLC Logo
Clinical-stage biopharma developing a novel class of bicyclic peptide medicines.
United States of America
BCYC
BIFIDO. Co. Ltd Logo
Biotechnology firm developing human-derived Bifidobacterium for various products.
South Korea
238200

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.